The Efficacy of Pro- and Anticoagulant Therapy in Plasma of Patients with Cirrhosis undergoing Orthotopic Liver Transplantatio

Completed

• Conditions: bleeding; Thrombosis; 10019654; 10003184; 10014523

• Registration Number: NL-OMON42693
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Orthotopic Liver Transplantation for cirrhosis at the UMCG
Age >18 years
Signed informed consent

Exclusion Criteria

Acute liver failure
Documented history of hereditary thrombophilia
Use of vitamin K antagonists
Transfusion of blood products (<7 days)
Deep venous thrombosis (<30 days)

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Thrombin generation by Calibrated Automated Thrombinography.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Other study parameters are individual coagulation factors, Prothrombin Time<br /><br>(PT), International Normalized Ratio (INR), Activated Partial Thromboplastin<br /><br>Time (APTT), Fibrinogen, Platelet count and Hemoglobin (Hb). Moreover,<br /><br>indicators of liver function such as Gamma-Glutamyl Transpeptidase (GGT),<br /><br>Asparate Aminotransferase (ALT) Alanine Transaminase (AST), ammonia (NH3),<br /><br>alpha1 antitrypsin and ceruloplasmin are study parameters.</p><br>